Table 2.

Summary of patients with arterial and venous thromboembolic complications.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8
Event	MCI/PVT	Ischemic stroke	DVT/PVT	DVT/PVT	DVT	PE	DVT	PE
CPS	B	A	A	A	A	A	B	A
BCLC	C	C	C	C	C	A	C	C
Etiology	Unknown	Viral	ALD	ALD	Unknown	Unknown	ALD	Unknown
Macrovascular Invasion	Yes	Yes	No	Yes	Yes	No	Yes	Yes
Extrahepatic Metastases	No	No	Yes	Yes	Yes	No	No	No
AFP (IU/mL)	3.8	2.5	31.8	-	866.0	-	-	17,312.0
Known coronary heart disease	No	No	No	No	No	No	No	No
Known arterial occlusive disease	No	Yes	No	Yes	No	No	No	No
Diabetes mellitus	No	Yes	No	No	Yes	Yes	Yes	No
Arterial hypertension	No	Yes	No	No	No	Yes	No	No
Framingham risk score points (risk, %)	11 (7.3%)	17 (29.4%)	N/A	N/A	N/A	N/A	N/A	N/A
Framingham risk class	Low	High	Low	High	High	N/A	High	N/A
Time to (first) event (months)	1.4	19.6	15.9	3.8	3.8	3.4	2.7	11.0
Sorafenib Dose at event (mg)	800	200	800	800	400	800	800	400
Event Management	Sorafenib: Discontinued	Sorafenib: Interrupted	Sorafenib: Continued				Sorafenib: Continued	Sorafenib: Continued
	Medical treatment: DAPT (ASA + Clopidogrel)	Medical treatment: none	Medical treatment: anti-coagulation (LMWH)	N/A	N/A	N/A	Medical treatment: anti-coagulation (LMWH)	Medical treatment: anti-coagulation (LMWH)
	Intervention: PCI	Intervention: none	Intervention: none				Intervention: none	Intervention: none
Death within 14 days (yes/no)	Yes	No	No	No	Yes	No	No	No

Abbreviations: AFP, α-fetoprotein; ALD, alcoholic liver disease; AOD, arterial occlusive disease; ASA, acetylsalicylic acid; BCLC, Barcelona Clinic Liver Cancer; CPS, Child–Pugh Score; DAPT, dual anti-platelet therapy; DM, diabetes mellitus; DVT, deep vein thrombosis; LMWH, low molecular weight heparin; MCI, myocardial infarction, N/A, not available; PE, pulmonary embolism; PVT, portal vein thrombosis.